Selective COX -2 inhibitors reduce adenoma formation and cancer progression in rodent models of colorectal cancer. To assess the therapeutic activity of selective COX -2 inhibitors, we tested the effect of SC -58125 treatment on the growth of human colon carcinoma cells in nude mice. Delaying treatment by 2, 4, or 7 weeks following implantation of the carcinoma cells resulted in a significant inhibition of tumor growth. Furthermore, short -term ( 48 hours ) treatment with SC -58125 was sufficient to attenuate tumor growth for up to 15 days. SC -58125 treatment did not alter the rate at which cells underwent apoptosis, but did result in a delayed progression through the cell cycle at the G 2 / M transition. Accordingly, p34
Introduction
Americans have a 1 -in -20 lifetime risk of developing colorectal cancer [ 4 ] . This disease is often detected at a late stage when treatment is costly and the clinical outcome is poor. Development of better prevention and therapeutic strategies is critical to improve the prognosis for patients with colorectal cancer. Non -steroidal anti -inflammatory drugs ( NSAIDs ) represent one class of chemopreventive agents, which have activity against colorectal cancer. Numerous epidemiologic, animal, and clinical studies have shown that NSAIDs reduce the risk of colorectal cancer [ 7, 8, 16, 26 ] . Sulindac sulfide is a non -selective cyclooxygenase inhibitor (IC 50 ratio COX -1 / COX -2 = 0.258 ) [ 28 ] and has been shown to reduce adenoma number in rodent models of intestinal cancer such as the Min mouse and the azoxymethane ( AOM ) -treated rat [ 2, 18 ] . Sulindac has also been shown to reduce the size and number of polyps in patients with Familial Adenomatous Polyposis [ 7 ] . One known target for this class of drugs is the cyclooxygenase enzyme. There are two isoforms of this enzyme, cyclooxygenase -1 ( COX -1 ) and cyclooxygenase -2 ( COX -2 ), which are key enzymes for the production of prostaglandins. COX -1 is constitutively expressed at low levels in many tissues, and it is believed that inhibition of COX -1 leads to the pro -ulcerogenic effect seen after prolonged NSAID use in humans [ 19 ] . COX -2 is constitutively expressed in some organs ( i.e., brain and kidney ); however, this isoform is rapidly and transiently induced by a variety of stimuli in numerous tissues and cell types. COX -2 is not expressed in the normal colon or small bowel; however, early neoplastic lesions constitutively express this isoform [ 6 ] .
Selective inhibition of COX -2 blocks growth of human colon carcinoma xenografts in mice and carcinogeninduced colon tumors in rats [ 9, 11, 17, 20 ] . The hypothesis that COX -2 is causally related to colorectal carcinogenesis was evaluated using a genetic mouse model for colorectal cancer. Oshima et al. [ 14 ] found that when adenomatous polyposis coli ( APC Á716 ) mutant mice were bred onto a COX -2 -deficient background, the tumor multiplicity was reduced by nine -fold. Additionally, APC Á716 mutant mice treated with a selective COX -2 inhibitor showed a marked reduction in tumor number as well. Therefore, treatment with a selective COX -2 inhibitor can have an effect at early stages in the development of intestinal cancer; however, the efficacy of treating established colorectal carcinomas with selective COX -2 inhibitors has not been thoroughly evaluated.
In the experiments described here, we test the hypothesis that treatment with a selective ( SC -58125 ) or non -selective ( sulindac sulfide ) COX -2 inhibitor could alter the growth of pre -existing carcinomas. We found that treatment with SC -58125 blocked the growth of carcinoma cells by causing a delay in the transition through the G 2 / M phase of the cell cycle with a reduction in p34 cdc2 levels. This work demonstrates that SC -58125 effectively inhibits the growth of established tumors. Hopefully, these results will stimulate
Cell Culture HCA -7 cells ( a generous gift from Sue Kirkland ) were derived from a human rectal cancer. Lewis lung carcinoma ( LLC ) cells were originally derived from a spontaneous lung carcinoma in a C57 / BL6 mouse and were purchased from the American Type Culture Collection ( CRL -1642; ATCC, Manassas, VA ). Both cell lines were maintained in Dulbecco's modified Eagle's media ( DMEM; Gibco BRL Gaithersburg, MD ) containing 10% fetal bovine serum ( Hyclone Laboratories, Ogden, UT ), 100 U / ml penicillin, and 100 g/ ml streptomycin ( 1% Pen / Strep; Gibco BRL ).
Xenograft Tumor Growth
HCA -7 cells were grown on plastic culture dishes according to standard cell culture techniques [ 20 ] . The cells were trypsinized, resuspended in sterile phosphate -buffered saline ( PBS ), and then pelleted by brief centrifugation at 1800 rpm. The supernatant was aspirated and cells resuspended in sterile PBS and counted manually using a hemocytometer. Cells were resuspended in PBS to a final concentration of 5Â10 7 cells / ml, and 100 l of cell suspension was injected subcutaneously into the dorsal flank of athymic mice ( Harlan Sprague -Dawley, Indianapolis, IN ) using a 27 -gauge needle. The size of the tumor was determined at 1 -week intervals by direct measurement of tumor dimensions. SC -58125 was dissolved in DMSO and injected intraperitoneally at a dose of 10 mg / kg. Tumor volume was determined by external measurement and calculated according to the equation
where V = volume, L = length, and W = width [ 27 ] .
Prostaglandin Measurements
Tumor PGE 2 levels were measured using GC mass spectroscopy as previously described [ 20 ] . The limit of sensitivity for detection of PGE 2 is 4 pg / ml.
Immunoblotting
Western blot analysis of protein lysates was performed as previously described [ 5 ] . Briefly, cells were lysed for 30 minutes in RIPA buffer ( 1Â PBS, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [ SDS ], 10 mg / ml ), then clarified cell lysates ( 100 g ), and were denatured and fractionated by 10% SDS -PAGE. After electrophoresis, the proteins were transferred to PVDF filters. The filters were blocked for 3 hours in Blotto ( 0.15 M NaCl, 10 mM Tris -HCl, pH 7.4, 0.1% Tween -20, 5% nonfat dry milk ), and then incubated overnight with either COX -1 ( N -20 SC -1753; Santa Cruz Biotechnology, Santa Cruz, CA ), COX -2 ( N -20 SC -1746; Santa Cruz Biotechnology ), or p34 cdc2 ( 17 SC -54; Santa Cruz Biotechnology ) -specific antibodies. The membranes were washed in TBST ( 0.15 M NaCl, 10 mM Tris -HCl, pH 7.4, 0.1% Tween -20 ). The membranes were then incubated with an HRP -conjugated donkey antigoat secondary antibody for 45 minutes, then washed three times, 15 minutes each with TBST before processing using the ECL chemiluminescence system ( Amersham, Arlington Heights, IL ) and exposed to XAR -5 film ( Kodak, New Haven, CT ).
Apoptosis Measurements
In the xenograft experiments, apoptotic cells were identified in vivo as scattered single cells with a condensed cytoplasm and either a pyknotic or fragmented nucleus. Apoptotic cells in 10 high -power fields ( Â400 ) were counted 24 hours after the last SC -58125 treatment, and the mean number of apoptotic cells per high -power field was calculated. Each slide was counted twice and, if more than a 10% discrepancy in the mean number of apoptotic cells was found, the slide was re -counted until two successive measurements were within 10% agreement.
In all culture experiments, apoptosis was evaluated using three independent methodologies: TUNEL assay, DNA laddering, and Annexin V staining. TUNEL assays were performed using two separate systems: the in situ cell death detection kit ( POD; Boehringer Mannheim, Ridgefield, CT ), for evaluation of apoptotic cells in situ, and the APO -Direct kit ( Pharmingen, San Diego, CA ), for quantitative evaluation of apoptosis. For in situ apoptosis evaluation, HCA -7 or LLC cells were grown on coverslips then treated with either 25, 50, or 100 M SC -58125 ( G.D. Searle, St. Louis, MO ) or an equivalent volume of vehicle ( DMSO ). After drug treatment, medium was discarded and the cells were washed and fixed in 4% paraformaldehyde in PBS for 30 minutes at room temperature ( RT ). Cells were incubated with 0.3% H 2 O 2 in methanol for 30 minutes at RT to block endogenous peroxidase activity. The number of positive ( apoptotic ) cells was analyzed by light microscopy. Flow cytometric detection of fluorescein -labeled fragmented DNA was conducted to quantitatively evaluate apoptosis in response to SC -58125 treatment. LLC or HCA -7 cells were seeded in 100 -mm plates and, when 80% confluent, they were treated with DMSO or 100 M SC -58125. Negative control cells were not treated and positive control cells were treated with 50 M SC -58635 for 24 hours. Cells were harvested at 12 and 24 hours, washed in PBS two times, then fixed in 1% paraformaldehyde for 15 minutes and permeabilized by addition of ice -cold 70% ethanol. The APO -DIRECT kit was used to end -label fragmented DNA with FITC -conjugated dUTP as substrate. The labeling reaction was performed according to the manufacturer's recommendations with the exception that 3Â10 6 cells per condition were used. After labeling, cells were washed three times in PBS, then resuspended in 1 ml propidium iodide ( PI ) staining solution (5 g / ml PI, 40 g / ml RNASE A, in 1Â PBS ). Cells were then filtered through 50 -m mesh immediately prior to analysis on a Becton Dickinson FACScan flow cytometer. Gating on FL2 width was used to exclude aggregates, and 10 4 gated events were collected and analyzed.
Additionally, the ability of SC -58125 to induce apoptosis was evaluated by testing for the presence of nucleosomal
laddering of DNA. An equal number of cells were plated in 60 -mm diameter culture dishes. At different times following treatment with vehicle or SC -58125, attached and floating cells were collected, centrifuged, and washed with PBS. DNA was extracted using the PureGene purification kit ( Gentra Systems, Minneapolis, MN ) according to the manufacturer's protocol. Tris phosphate EDTA ( TPE ) agarose gels ( 1.5% ) were prepared using multipurpose agarose according to the manufacturer's recommendations. DNA samples were prepared in a neutral loading buffer ( 0.25% bromophenol blue, 0.25% xylene cyanol, and 30% glycerol in water ), and the DNA samples were electrophoresed and visualized by UV illumination.
In Vitro Proliferation Assays
The 3 -( 4,5 -dimethylthiazol -2 -yl -2,5 -diphenyltetrazolium bromide ) ( MTT ) assay was employed to determine cell viability / proliferation. This assay is a measure of mitochondrial activity; MTT is a yellow -colored tetrazolium salt that is taken up and cleaved only by metabolically active cells, reducing it to a colored, water -insoluble formazan salt. The solubilized formazan product can be quantified via absorbance at 570 nm measured using a 96 well -format spectrophotometer and the absorbance correlates directly with cell number. Cells were seeded at 2Â10 4 
cells / well in a 100
l volume in 96 -well plates and grown for 24 hours in DMEM supplemented with 10% FBS. The indicated amount of SC -58125 or DMSO in 1% FBS containing OptiMEM media was then added to the wells. At the indicated times, 10 l MTT ( 5 mg / ml ) was added and the cells were incubated at 378C for 4 hours. The tetrazolium crystals were solubilized by addition of 10% SDS in 0.01 N HCl. After overnight incubation at 378C, the optical density was measured at 570 nm using a 96 -well spectrophotometric plate reader ( Packard Instruments, Meriden, CT ). Results represent the mean ± SD of six wells from one experiment and are representative of experiments repeated at least three times.
Flow Cytometric Analysis
After treatment with either DMSO ( vehicle ) or SC -58125, HCA -7 cells were trypsinized at the indicated times with 500 l of 2 mg / ml trypsin / 0.02% EDTA for 2 to 5 minutes, scraped, and pelleted by centrifugation at 1000g for 5 minutes. Cell pellets were washed twice in PBS, then pelleted and resuspended in 1 ml of PBS. Cells were passaged through a 21 -gauge needle 10 times to bring to a single cell suspension. Lewis lung carcinoma cells are a semi -adherent culture and did not require trypsinization or needle passage to obtain single cell suspensions. The cells were fixed by the addition of 1 ml of ice -cold 100% ethanol, which was added dropwise while gently vortexing the samples. An additional 1 ml of ethanol was then added and the samples stored at 48C for at least 2 hours. Cells were pelleted by centrifugation and washed one time in PBS and then resuspended in PI staining solution ( 0.5 mg / ml RNase A, 20 g / ml PI, in PBS ). Samples were stored at RT for 30 minutes then filtered through 50 -m filters to remove aggregates immediately prior to analysis. Flow cytometric analysis was performed using a FACScan cytometer ( Becton Dickinson, San Jose, CA ). Single cell populations were gated using forward scatter, an indicator of cell size versus side scatter, an indicator of cell granularity. The FL2 detector measures fluorescent light from PI, and PI intensity is proportional to the DNA content of the cell. The FL2 -PI area versus width plots distinguished true cycling G 2 / M cells from doublets or aggregates of G 0 / G 1 cells by comparison to standardized area versus width plots and were adjusted in all experiments. Cell Quest Software ( Becton and Dickinson Immunocytometry System ) was used to control the collection of data from at least 10,000 cells per sample at low flow rate ( 12 l / min ), and DNA data were analyzed with ModFit software ( Verity Software House, Popsham, ME ).
Dual parameter flow cytometry was used to assess the effect of SC -58125 on the proliferation rate of LLC cells. Cells were plated and allowed to attach for 24 hours then pulsed for 45 minutes with 10 M BrdU ( In Situ Cell Proliferation Kit, FLOUS; Boehringer Mannheim ). Cells were washed two times in PBS and growth media were replaced with OptiMEM media ( Gibco BRL ) supplemented with 1% FBS with either vehicle ( DMSO ) or the indicated amount of SC -58125. Cells were treated for the indicated times then harvested either by trypsinization, as described above for the HCA -7 cells, or by gentle washing with media ( LLC cells ). Cells were fixed and prepared as described by Becton Dickinson's dual parameter BrdU / PI protocol. An isotypematched ( IgG 2 ) FITC -conjugated control antibody was used to determine and adjust for background FITC fluorescence. Cells were filtered through a 50 -m mesh filter and then 10,000 gated events were collected using a Becton Dickinson FACScan flow cytometer. Analysis was performed using FlowJo ( TreeStar, Palo Alto, CA ).
Mitotic Figure Determination
Mitotic cells were identified by assessing nuclear changes using the nuclear binding dye 4 0 ,6 -diamidino -2 -phenylindole ( DAPI ) dihydrochloride and fluorescence microscopy. Ten high -power fields were counted per condition and the average is presented ± SD. After 12 hours of treatment, the cells were fixed, the number of mitotic figures per high power field was counted, and a mitotic index was calculated.
Differential Gene Expression
Total RNA was isolated from vehicle and SC -58125 -treated cells using the Tri -Reagent extraction method ( MRC Research, Cincinatti, OH ). Total RNA ( 5 g ) was primed with oligo dT ( Research Genetics, Huntsville, AL ), and reverse -transcribed with Superscript II RT ( Gibco BRL ) in the presence of [ 33 P ]dCTP ( ICN, Costa Mesa, CA ). The resultant probes were hybridized to cDNA microarrayed onto a nylon membrane ( GENEFILTERS release 200; Research Genetics ) for 16 hours. After washing, the membrane was exposed to a phosphorimage screen ( Cyclone Storage Phosphor System; Packard Instruments ). Images were imported into the PATHWAYS analysis program ( Research Genetics ) and analyzed for differential gene expression. Differential expression was confirmed by Northern blotting of total RNA ( 20 g ), which was separated on formaldehyde agarose gels and blotted onto nitrocellulose filters. A probe was generated by random primer extension using [ 32 P ]dCTP of a cDNA fragment derived from the 3 0 UTR of human p34 cdc2 . Blots were washed then imaged using the Cyclone phosphorimaging system ( Packard Instruments ).
Statistical Methods
The significance of the effect of treatment on xenograft growth was determined using repeated measures ANOVA and the Statview analysis package ( SAS Institute, Cary, NC ). The Students' t -test was employed to compare the difference in means between various groups.
Results

SC -58125 Treatment of Established Colorectal Carcinoma Xenografts
We have previously reported that HCA -7 xenograft growth was attenuated when mice were treated with SC -58125 at the time of tumor engraftment [ 20 ] . In order to evaluate the effectiveness of SC -58125 at inhibiting established HCA -7 xenograft growth, mice were treated at the time of tumor implantation or 2 and 4 weeks later. Vehicle -treated mice exhibited a tumor volume doubling time of 2.6 weeks ( Figure 1A ). We observed a statistically significant decrease in the tumor growth rates in all of the SC -58125 -treated mice when compared to controls ( P < .0001 ). Inhibition of xenograft growth was evident within 1 week following initiation of treatment. Therefore, SC -58125 treatment of established tumors resulted in attenuation of tumor growth.
We next sought to compare the effect of a non -selective COX inhibitor, sulindac sulfide, and a COX -2 -selective inhibitor, SC -58125, on xenograft growth. HCA -7 cells were implanted into nude mice and, at 7 weeks following implantation, the mice were divided into three groups: 1 ) control, 2 ) SC -58125, or 3 ) sulindac sulfide. Both SC -58125 . SC -58125 reduces tumor PGE 2 levels. In order to determine the efficacy of SC -58125 treatment, the PGE 2 concentrations were monitored in the tumor. Mice were sacrificed at 2, 4, 6, 12, 24, 36, and 48 hours following SC -58125 treatment ( 10 mg / kg ). Tumors were excised and flash -frozen in liquid nitrogen. PGE 2 levels were determined by gas chromatograph mass spectroscopy and expressed as ng PGE 2 / pg protein. and sulindac sulfide treatment inhibited xenograft growth to the same extent ( Figure 1B ) .
The effectiveness of short -term SC -58125 treatment on tumor growth was then evaluated. HCA -7 xenografts were implanted and, after 1 week, SC -58125 was given once per day for 2 days and then discontinued. To our surprise, xenograft growth was arrested by this treatment strategy ( Figure 1B, insert ) . However, by day 18 following this transient treatment regimen, the tumors had returned to control growth rates. To determine the effect of SC -58125 on tumor prostaglandin levels, PGE 2 was measured at 2, 4, 6, 12, 24, 36, and 48 hours following SC -58125 treatment ( Figure 2 ) . A significant reduction in PGE 2 was observed within 2 hours of treatment with maximal inhibition occurring at 12 hours. PGE 2 levels remained low for 24 hours and then began to increase, reaching 50% of initial levels within 36 hours following treatment. Therefore, SC -58125 effectively inhibited prostaglandin synthesis in the xenografted carcinomas, indicating that the drug was well distributed to the tumor site.
It has been reported that treatment of cells with nonselective NSAIDs can alter the expression of COX -2 [ 12 ] . It is possible that the decrease in PGE 2 levels shown in Figure  2 may be due, in part, to alterations in the levels of COX -2. To evaluate this possibility, we extracted protein from the tumors and measured COX -1 or COX -2 levels in the xenografted carcinomas by Western blot analysis ( Figure 3 ). There was no detectable COX -1 protein in HCA -7 xenografts; however, COX -2 was present and its level did not change following SC -58125 treatment. Therefore, since COX -1 was not detected and COX -2 levels did not change, it is most likely that the decrease in PGE 2 is due to inhibition of COX -2 activity by SC -58125.
Hypothetically, SC -58125 treatment could cause a reduction in tumor size by decreasing proliferation and / or increasing apoptosis rates within the tumor. To determine if SC -58125 treatment increased the number of cells undergoing programmed cell death, apoptotic figures from hematoxylin -and eosin -stained sections from control and SC -58125 tumors were counted and compared. No significant difference in the number of apoptotic cells was observed ( Table 1 ) .
In summary, we demonstrate that SC -58125 treatment inhibits the growth of established tumors and that as few as two treatments significantly attenuate tumor growth. SC -58125 did not have a significant effect on the rate of cells undergoing apoptosis in vivo as measured by apoptotic index of SC -58125 -treated xenografts. This result was surprising since other NSAIDs have been shown to stimulate carcinoma cell to undergo apoptotic cell death. Growth inhibition was associated with a reduction in PGE 2 production without any change in the level of COX -2 protein.
Proliferation Assays
To determine the effect of SC -58125 on the growth of carcinoma cells, we studied both the HCA -7 and LLC cells. COX -1 and COX -2 are expressed constitutively at high levels in the LLC cells. SC -58125 was not toxic to these cells even when treated for up to 3 days at 100 M dose ( Figure  4A ) and no change in cell viability was seen as determined by trypan blue exclusion ( data not shown ). We measured both cell counts ( Figure 4B ) and MTT activity ( Figure 4C ) to evaluate the effect of SC -58125 treatment on cell growth. The MTT assay provides a measure of cell viability because conversion of the MTT substrate to formazan crystals requires intact and functional mitochondria. We observed an SC -58125 dose -dependent reduction in cell number and MTT activity in both cell lines ( Figure 4B and C ) ; however, LLC cells were more sensitive than HCA -7 cells to treatment with SC -58125. We determined that the effect of treatment on the number of cells undergoing programmed cell death was not significant using the TUNEL assay ( Figure 5 ), DNA laddering ( data not shown ), and annexin V staining ( data not shown ).
Effect of SC -58125 Treatment on Cell Cycle Distribution
We next examined the effect of SC -58125 on LLC cell cycle distribution using flow cytometry. We observed a profound dose -and time -dependent increase in the number of cells containing 4n DNA content following treatment with SC -58125 ( Figure 6A and B ). An increase in 4n DNA content was found as early as 4 hours after treatment with doses as low as 25 M. To determine if this was due to a mitotic block, LLC cells were treated with SC -58125 or sulindac sulfide and the mitotic indices were calculated. There was a significant reduction in the number of mitotic figures in the SC -58125 -treated cells, indicating that the increase in 4n DNA content was due to a late S -or G 2 -phase block ( Figure 6C ) . Interestingly, when similar experiments were performed on the HCA -7 cells, an increase in 4n DNA content was not observed. However, there was an increase in the S -phase assigned fraction ( data not shown ). This result may be due to technical problems associated with HCA -7 cell preparation for cell flow analysis because the adherence properties of HCA -7 cells make it difficult to obtain pure single cell suspensions.
To directly test the effect of SC -58125 on cell proliferation, we pulse -labeled HCA -7 and LLC cells with BrdU and then added SC -58125 to the medium. In the LLC cells, 12 hours of treatment with SC -58125 resulted in an increase in the number of cells in late S / G 2 with virtually no labeled cells reaching the mitotic phase of the cell cycle ( Figure 7A ). Interestingly, 18 hours following treatment, this G 2 / M arrest was partially overcome, indicating an incomplete block ( Figure 7B ) . A similar effect was observed in the HCA -7 cells, though to a lesser degree, which correlates with the reduced sensitivity of HCA -7 cells to SC -58125. At 12 hours following treatment, there was a 2.5 -fold reduction in the . ( D ) In vitro H1 kinase assay. HCA -7 cell lysates were generated from cells treated for 3 days with SC -58125 of vehicle. Kinase activity was measured as previously described [ 23 ] .
fraction of labeled cells transiting into G 1 , and a partial escape was observed by 24 hours. We conclude from these studies that the primary effect of SC -58125 treatment on both LLC and HCA -7 cells is to inhibit cell proliferation.
Molecular Targets
High -density expression arrays were screened to determine if the expression of growth -regulating genes is affected by SC -58125 treatment of HCA -7 cells. The filter gene arrays were hybridized with [
32 P ] -labeled cDNA reverse -transcribed from mRNA isolated from either SC -58125 -or DMSO -treated HCA -7 cells. The expression levels of a number of genes were affected following treatment with SC -58125, and of particular interest to this study, the levels of p34 cdc2 mRNA were reduced in a dose -dependent fashion following SC -58125 treatment with 100 M SC -58125 resulted in a three -fold decrease in p34 cdc2 mRNA ( Figure   8A ). There are two splice variant forms of p34 cdc2 mRNA present ( Figure 8A ), which have been previously reported [ 25 ] . SC -58125 treatment also reduced p34 cdc2 mRNA ( Figure 8B ) and protein ( Figure 8C ) levels in HCA -7 xenografts as well. Histone H1 kinase is a substrate for p34 cdc2 . To determine whether SC -58125 modulated p34 cdc2 kinase activity, p34 cdc2 was immunoprecipitated from SC -58125 -treated and control HCA -7 cells and then phosphorylation levels of histone H1 -kinase by p34 cdc2 were determined. We found that SC -58125 treatment resulted in a dose -dependent decrease in kinase activity with strong inhibition, even at the lowest concentration of SC -58125 ( Figure 8D ). It is possible that the reduction in p34 cdc2 levels and activity following SC -58125 treatment may contribute to inhibition of cell proliferation.
Discussion
We have previously reported that treatment with SC -58125 inhibits the growth of colorectal cancer xenografts [ 20 ] . In those experiments, treatment was initiated at the time of tumor implantation and by starting treatment this early, the key effect could be primarily due to a reduction in graft attachment and survival. We also reported that SC -58125 treatment of cultured cells may result in a slight increase in apoptosis [ 21 ] . Therefore, we decided to evaluate the effect of SC -58125 on the growth of already established tumors in vivo. We found that when treatment was delayed either 2, 4, or 7 weeks after carcinoma cell implantation, that xenograft growth was significantly attenuated. Interestingly, delayed treatment resulted only in a cytostatic effect and neither SC -58125 nor sulindac sulfide led to tumor regression. In rodent models of colorectal cancer, where predisposition to cancer development can be increased by either genetic manipulation or carcinogen treatment, both selective and nonselective NSAIDs decrease tumor burden as well as stimulate regression of existing adenomas [ 1 -3,11,13 ] . Treating mice with established colon carcinoma xenografts may represent a more appropriate model in which to test therapeutic potential for NSAIDs and selective COX -2 inhibitors. Our results suggest that SC -58125 treatment of existing carcinomas is effective at inhibiting the expansion of tumor mass. Due to the limited toxicity of selective COX -2 inhibitors, these compounds may be useful in combination with existing chemotherapeutic drugs or ionizing radiation for the treatment of patients with colorectal cancer. The in vivo mechanism for action of SC -58125 has yet to be determined. Hypothetically, this compound could inhibit xenograft growth by inducing apoptosis, inhibiting proliferation, and / or by limiting a host -derived parameter such as angiogenesis or enhancing immune responses to the xenograft. It has recently been shown that LLC tumors grown in COX -2 knockout animals exhibit reduced growth rates then either wild -type and COX -2 heterozygote hosts. Therefore, SC -58125 might inhibit tumor growth, at least in part, by inhibiting host -derived COX -2. Sulindac sulfide has been shown to induce apoptosis in colorectal cancer cell lines in vitro and in adenomas in both the Min mouse and AOM -treated rat [ 13, 15, 18 ] . We did not observe an increase in apoptosis in sulindac sulfide -treated HCA -7 xenografts as measured by comparison of the quantity of apoptotic figures in control and SC -58125 -treated tumors. In one of our previous reports [ 21 ] , we did observe a slight modulation in the rate of cells undergoing apoptosis ( 0.7% increase ) in vitro following SC -58125 treatment. However, the effect of SC -58125 treatment on cell proliferation was not evaluated in that study and, in light of our current results, it seems more likely that the predominant effect of SC -58125 on HCA -7 and LLC cells is inhibition of their progression through the cell cycle.
SC -58125 inhibited the growth of both HCA -7 and LLC cells grown in culture by delaying transit through the G 2 phase of the cell cycle. Sulindac sulfide has been reported to induce a G 2 arrest in HCT -15 cells, followed by programmed cell death [ 10 ] . We observed a reduction in p34 cdc2 levels and activity following SC -58125 treatment. p34 cdc2 is a cyclin -dependent kinase and a key regulator of the transition of cells from the G 2 to M phase of the cell cycle. Downregulation of p34 cdc2 and G 1 arrest has been reported following treatment of cells with non -selective NSAIDs [ 22, 24 ] . In the experiments reported by Shiff et al. [ 22, 24 ] , NSAIDs such as sulindac, indomethacin, and aspirin caused a downregulation of p34 cdc2 , but it is not clear how this effect was related to the G 1 arrest and resultant induction of apoptosis. Our experimental results indicate that SC -58125 treatment led to an increase in the fraction of cells in the G 2 phase of the cell cycle. BrdU labeling studies confirmed that the block in G 2 was incomplete. A decrease in p34 cdc2 levels and activity may contribute to the delay in progression through the cell cycle and the resultant decrease in proliferation rate of both LLC and HCA -7 cells following SC -58125 treatment. In summary, we present evidence that treatment with SC -58125, a selective COX -2 inhibitor, reduced the growth of established colon carcinoma xenografts, resulting in tumor cytostasis. Here, we employ gene array technology to determine the alterations in carcinoma gene expression following treatment. In cell culture studies, SC -58125 treatNeoplasia . Vol. 3, No. 5, 2001 ment inhibited proliferation and led to an accumulation of cells in the G 2 phase of the cell cycle with a reduction in p34 cdc2 levels. Further studies will be required to determine whether other genes whose levels are altered by COX -2 inhibitor treatment may serve as useful intermediate markers for future cancer prevention and / or treatment trials in humans. Future studies may also be warranted in evaluating treatment regimens for colorectal cancer, which specifically target cells in specific phases of the cell cycle in combination with a selective COX -2 inhibitor.
